Navigation Links
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
Date:5/14/2009

Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulceration of the lining of the colon. Symptoms typically include bloody diarrhea and abdominal pain and in severe cases may require colectomy. According to the Crohn's & Colitis Foundation of America, it is estimated that there are up to approximately 500,000 Americans with ulcerative colitis.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved for commercial sale. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, the statements relating to MDX-1100 in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any futu
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  ViaCyte, Inc., a privately-held regenerative medicine ... treatment of diabetes in clinical trials, today announced the opening of ... or S afety, T olerability, and E fficacy ... Diabetes.  The new site, which is the first in ... in Edmonton , Alberta.  The ...
(Date:7/29/2015)... July 29, 2015  Fifty groups representing 500,000 patients, ... 29, to launch the AllTrials campaign in the US. ... present, and future, to be registered and the results ... Ben Goldacre explains: "Patients want the treatments ... evidence on what works. Unfortunately, we now know that ...
(Date:7/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/hmjqff/global_wound_care ) has ... Care Markets (Twelve Country Analysis: Germany, France, Italy, ... Brazil, Australia, South Korea)" report to their ... competitive market summary. The wound care market is ... product maturity. Several of the products within the ...
Breaking Medicine Technology:ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4Fixing Your Medicine: AllTrials Campaign Launches in US 2Fixing Your Medicine: AllTrials Campaign Launches in US 3Global Wound Care Markets 2015 2
... 29, 2011 , OBN BioCluster ... The UK bioindustry has raised over $250m in financing during the ... for one year, and the second largest amount raised in any ... financing drought that saw three consecutive quarters below $100m from the ...
... 29, 2011 Sales executives agree that delivering ... biopharmaceutical sales process. Yet despite the effectiveness of ... drug,s efficacy, only 6% of biopharmaceutical district sales ... of data to sales representatives, according to recent ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3Though Essential to Pharmaceutical Sales Success, the Use of Health Outcomes Data Often Overlooked by Sales Leaders 2
(Date:7/29/2015)... CA (PRWEB) , ... July 29, 2015 , ... We are privileged to announce that ... Medicine of USC as the ninth best ophthalmology hospital in the nation for 2015-2016. This ... 10 American hospitals for ophthalmology. , “It is an honor to be included in ...
(Date:7/29/2015)... ... July 29, 2015 , ... Inspired by a successful ... Steven W. Meier M.D., a prominent orthopedic surgeon and regenerative medicine expert in ... financial need. , “We are thrilled for this opportunity to offer prolotherapy treatments ...
(Date:7/29/2015)... ... July 29, 2015 , ... Stealth ... a Clinical Performance Study for the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, ... options, offers a less invasive, patient-friendly alternative to traditional chest ports and peripherally ...
(Date:7/29/2015)... ... July 29, 2015 , ... Zofran ... Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* Attorneys handling ... website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate ...
(Date:7/29/2015)... ... July 29, 2015 , ... The Woodlands and Spring ... lifestyles while donating to worthy charitable causes each month. The new system will track ... camp. For each Check In at each facility, the boot camps will donate 20 ...
Breaking Medicine News(10 mins):Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3
... your keys has its down sideSAN FRANCISCO, March 13 ... (Medical Sciences) indicate that convincing older drivers to give up ... study of 660 adults aged 63 to 97 showed that ... likely to die over a three-year period than their counterparts ...
... - The Boston Center for Refugee Health and ... treated many of the large number of Tibetan ... individuals arrived in Boston suffering from symptoms of ... monks were diagnosed by their traditional healers as ...
... - Haemacure Corporation (TSX : HAE) released today ... 31, 2009.ResultsRevenues amounted to $19,226, as compared to ... were exclusively derived from the sale of legacy ... $2.7 million, up from $1.2 million for the ...
... half of Americans know that the "better" fats (monounsaturated ... disease, according to a recent survey by the American ... at: http://inr.mediaseed.tv/aha_36307/ "Heart disease remains the No. ... lot about the ,bad, fats lately and what not ...
... occurred in ICUs , , THURSDAY, March 12 (HealthDay News) ... problem in intensive care units, a new study reveals. ... ICUs in 27 countries over a 24-hour period in ... included in the study. , Dr. Andreas Valentin of ...
... MESSA,s East Lansing-based ... consecutive year for superior efficiency and performance in providing ... providing efficient and effective customer service as measured against ... at Purdue University and BenchmarkPortal. "MESSA is ...
Cached Medicine News:Health News:Drive or Die 2Health News:Drive or Die 3Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 2Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 3Health News:Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company 2Health News:Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company 3Health News:VIDEO From Medialink and the American Heart Association: 'Better Fats' Benefit Heart Health 2Health News:Injected Medication Errors a Major Problem 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 2Health News:MESSA Receives National Recognition for Best Practices in Providing Efficient, Cost-Effective Customer Service 3
... HmX offers three-dimensional ... sensitivity, specificity and efficiency ... and reticulocyte analysis. With ... and dependability, HmX is ...
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL....
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
Medicine Products: